Heart Tronics Inc (HRTT)

[J-RO]

SGN on bottom watch today ~

Link back for chart :)

[TheRaveninexile]

Signalife awarded new U.S. patent for method to monitor heartbeats


Published: Wednesday, 23-Apr-2008



Medical Patent News


Signalife, Inc. has announced that the United States Patent and Trademark Office has awarded the Company a new and important patent entitled "System For, And Method Of, Monitoring Heartbeats Of A Patient". The patent, which covers 37 claims, will enhance the Company's ability to develop new proprietary products.

Patent attorneys from Fulwider & Patton supervised and executed the patent application along with Chief Technology Officer Budimir S. Drakulic -- the inventor of the patented technology. The new patent is owned by Signalife, Inc. In conjunction with the Patent Office's granting of the patent, the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.

Budimir S. Drakulic called the patent-issuance-development a "major milestone in the continued proliferation and protection of the Company's core technologies and products." Dr. Drakulic continued to say that issued patents together with significant patent portfolio already submitted to the United States Patent Office and two Frost & Sullivan technology awards represent major achievements for a young medical device company.

The Company currently has several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is "confident the Company will continue to be successful in obtaining approvals for pending patents of its technologies and products."

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

http://www.news-medical.net/?id=37685

[J-RO]

SGN ~> Popped up on scan. Watchlisted again.

Link back for chart.

[ChangeDirector]

It was just a clearly orchestrated pump and dump, that's all.

[AVDI_1]

well, we need to change the current activity level, to one of participation and communication. There is currently a great deal going on with SGN. I believe there is change in the wind, a new direction for the company which would start with a change in management. This should be a great buying opportunity for everyone....but it will probably take news for this to really happen.

[TechKim]

It was never a very active message board.

[TheRaveninexile]

Naaaa, everyone is getting ready to buy. Just watch.

[AVDI_1]

it appears that everyone who was posting here before has now sold and moved on....Huuuuuuummmmmm! now that is a novel thought....

[AVDI_1]

can someone please tell me what the heck is going on with our SGN.....i see that the web cast really help stimulate stock momentum, however, it appears that the momentum is going in the wrong direction. Would be nice for corp to come out with news that should have been included in the Tuesdays web cast. i think this is what you call "going down the toilet"....LTF

[ChangeDirector]

Maybe today is the day everyone finally took profit lol.

[TheRaveninexile]

I didn't get to actually see the webcast because I was at work yesterday, however my best friend watched it for me and said that although it was low key that the sales projections we conservatively $70 million in sales by the 4th quarter.

For a company that produced no revenue in 2007 to come out of the gate with $70+M in revenue in year one of production? There's no problem here nor is anything screwed up.

The people trading on T/A who wanted their profit got out yesterday.

[AVDI_1]

would someone please tell me how things got so screwed up today. The web cast was a serious disappointment and could have generated a tremendous amount of excitement for the company and the stock. So much for Doctors who can't market their product and the company at the same time.

you only get a few good shots in life and each one needs to count or pretty soon your just firing blanks.

[ChangeDirector]

Sheesh, saw that one coming a mile away at least.

[TheRaveninexile]

SIGNALIFE’s New ECG Technology: Advances Patient and Consumer Heart Care

[It Expands Clinical And Medical Cardiac Research Opportunity] Summary: A truly disturbing fact is the vast majority of ECG recording doctors are using to make diagnosis lack accuracy. If ones raw data isn’t sound, then it is irresponsible to make decisions based on that data. Inaccurate data becomes even more dangerous when it is plugged into systems that magnify it, and quickly provide it to physicians as a basis for diagnosis and treatment. Unfortunately, this is what has occurred during the evolution of most existing ECG systems.

Introduction
Since introduction in clinical settings, the long-term goals of electrocardiography has been the noninvasive detection of the presence of heart disease, the classification and characterization of disease, and the monitoring of cardiac function to assess change in cardiac state or effect of therapy [1]. Somewhere along the way most existing manufacturers loss site of the long term goal, and became sidetracked by the development of non-core technologies. Over time, this lack of focus has led to a sacrifice in the quality of data collected and then used by doctors. The ironic return for sacrificing the integrity of the data has been faster and more powerful tools to interpret and display said inaccurate data; such as auto-interpretation, data filters, computer averaging, electrical axis determination and interval measurement.

The disastrous result is that currently more emphasis is being put on less accurate data in the world of ECGs. The vast majority of healthcare intuitions have inaccurate data being fed into inpatient telemetry systems. Systems used for Heart trend reporting e,g. ST segments and other waveform data that are connected to ST and other alarms parameters, and often integrated with hemodynamic and other monitoring equipment.

We are all aware that if your raw data isn’t sound, then there isn’t any use in developing systems to interpret it. Unfortunately, as technology advanced providing filters and computer averaging, it hid the fact that the raw data was potentially distorted. This point; however, was not lost in the Signalife’s patented technology. A technology that uses a unique approach to acquire accurate data first and foremost, ensuring the most accurate information is available for making a diagnosis.

Signalife’s patented technology provides a unique platform for biomedical signal acquisition, classification, and evaluation of treatment for cardiovascular diseases. This platforms allows for a more accurate and precise identification of changes in cardiac function than any other ECG system in existence. The Fidelity ECG system(s) is based on patented technology that covers the full spectrum of cardiac frequencies. This system [2] allows for better-quality data by avoiding problems that exist in all other systems. The
Fidelity technology controls baseline wandering that distorts the heart's signal. The system does not involve filters, computer averaging, or any reconstruction of any portion of the ECG waveform. Being the only technology on the market not to use filters and techniques to mask the data is pertinent today. Kligfield and Okin [3] recently concluded there is a highly prevalent and likely widespread problem of improper filter settings being used in routine electrocardiography. This particular issue should be of tremendous concern to any risk management department.

History of technology
Signalife’s current patented technology was developed over a number of years. The original signal processing technology was developed in the early 1990s for the U.S. Air Force and NASA to enable recording of pilots’ brainwaves in the harsh environment of the jet airplane cockpits. The technology was further improved and used in sleep recorder devices that would enable home-based sleep studies. Signalife’s research and development team adjusted certain parameters of this technology to provide what is currently considered clinical-quality electrocardiographic recordings in ambulatory, exercise stress testing, and ultimately continuous 24/7 monitoring. Although many feel Signalife’s technology could set new standards of what is considered clinical-quality electrocardiographic recordings, but that shall remain speculation for now. What is clear is that the technology has been shown to produce a more accurate recording than other systems on the market [7], [8], [9].

Superior performance
Signalife technology has demonstrated superior performance over other systems on the market time and time again. Most ECG manufacturers have taken the classic, fundamentally flawed, approach to capturing an ECG. First they get a complete acquisition of the biomedical signal, and then on the back end they use digital filters to remove noise and provide a “clean” signal, that appears accurate but isn’t, i.e. “to improve cosmetic appearance of ECG tracing” [3]. The major problem with this approach is that it allows an unacceptable amount of baseline wander and a significant amount of distortion of the ECG data [12]. Signalife has a better approach to signal acquisition that does not rely on digital filters and keeps base line wander under control. Note, the use of digital filters not only reduces the noise but it removes a piece of the real information in the ECG. In addition, different digital filters can mimic heart disease not present in original ECG signal [12]. Signalife’s system provides more accurate data by relying on a front-end amplification system. Signalife prides itself on capturing correct data upfront, so it doesn’t need to be “cleaned” later. Signalife’s technology is optimized for different requirements of each step during signal acquisition, providing a much better tool for diagnoses. [3]

Signalife is a company which chose the correct approach to noninvasive detection of the presence of heart disease, the classification and characterization of disease, and the monitoring of cardiac function to assess change in cardiac state or effect of therapy.

In April of 2004, a group of authors from the FDA presented a position paper at 29th Annual Conference of the International Society for Computerized Electrocardiology (ISCE) describing a “new ambulatory recording system;” i.e. the Signalife system, that can become another source for diagnostic-quality 12-lead ECG records[2].

Signalife’s approach, its “new system,” is exactly what makes it better than anything else on the market. The Fidelity system differentiates it from all other ECG systems. In fact, not one company in the world does or even claims to match the ECG signals of Signalife's Fidelity 100. This is why no existing system or company represents competition for Signalife's Fidelity 100. This includes Phillips, Siemens, GE, and all other 12 lead ECG monitoring systems in the marketplace today. When it comes to ECG, Signalife’s new system is simply better at getting the intended job done. To highlight this point, I would note that all low-end frequencies between .05 and .5 Hz and high-end frequencies above 40 Hz to 150 Hz are basically excluded by existing ECG equipment. Further, most systems do not comply with the ECG guidelines issued by the American Heart Association [3], [4].

The Fidelity 100 can account for minimal ECG voltage changes i.e. 5 μV changes while others requiring changes of over 20 to 40 μV. This is pivotal for detecting myocardial ischemia in heart muscle. The cardiac ischemia is reflected by ST segment elevations and/or other distortions of the ST segment as well as other segments of the ECG waveform. It is Fidelity 100's specificity and sensitivity that allows the acquisition of a clean and undistorted heart signal. This is why the Fidelity 100 out performs all other ECG monitors. These facts become extremely important when monitoring high-risk cardiac patients not only in a pre-hospital setting, but during their hospital stay as well as in post discharge monitoring.

In regards to Signalife, one can say that no system approaches this quality and provides the physician with an accurate 12 lead ambulatory diagnostic recording. The Fidelity 100 provides the data that you need while the heart is under stress to properly characterize the signals coming from the heart to allow the development of a proper treatment plan for the patient. This is what cardiac care is all about i.e. reducing errors in providing the basic information needed for more accurate diagnosis and treatment. This translates into better care and a higher quality of life for the patient.

The Fidelity 100
During initial clinical evaluation, Fidelity 100 was used to provide a continuous ECG monitoring of ischemic episodes for Signalife’s Device Implementation, Validation, and Application (DIVA) program at Duke Clinical Research Institute at Duke University. In laboratory testing, using database of simulated ECG signals, the Fidelity 100 has outperformed competitors’ electrocardiographs in ability to faithfully reproduce original ECG signal. The results from DIVA study and field use of the Fidelity 100, demonstrate that Signalife Fidelity 100 outperformed well-known ECG recorders made by GE, Philips, Mortara, Siemens and NorthEast Monitoring [7], [8], [9].

Modified Fidelity 100 using the same patented technology was used to record surface ECG and intracardiac signals during electrophysiological studies at Cleveland Clinic. A group of authors from Cleveland Clinic and Signalife presented their work during 2006 Heart and Rhythm Society (HRS) meeting in Boston, Massachusetts [10]. The recordings obtained using Signalife technology demonstrated higher fidelity signals compared to the recordings from GE Prucka system, a widely used system. Following the Cleveland Clinic/Signalife presentation at the 2006 (HRS), a scientist from Medtronic approached Signalife R&D team inquiring about the Signalife technology and Fidelity 100. After demonstrating the Fidelity 100 at the Beth Israel Deaconess Medical
Center in Boston, Massachusetts, the Principal Investigator from the Center and the scientist from Medtronic selected Fidelity 100 over GE MAC 5000 for ECG recorder that will be used in a Medtronic study.

Later that same year, the Signalife technology was put through the arduous test when Olympic Gold medalist and a Super Bowl winner, Willie Gault, ran on a treadmill while wearing the Fidelity 100 [11]. This demonstration drew attention and awe of many attendees of the 2006 American Heart Association Scientific Sessions, including a large number of Signalife competitors.

Fidelity 200
Signalife has continued down the path toward noninvasive detection of the presence of heart disease, the classification and characterization of disease, and the monitoring of cardiac function to assess change in cardiac state or effect of therapy by applying its technology to an event monitor. Signalife has now received FDA 510(k) clearance to market and sell, without prescription, its ambulatory event recorder throughout the United States. This device is a direct-to-consumer non-prescription flexible credit cardsized heart monitoring device which will be used as an early-detection device by patients who desire to independently monitor their condition. The HeartLife Tempo Card uses the award-winning technology contained in Signalife's Fidelity 100 Heart Monitor. In operation, at the onset of an event that will be recorded, the patient will hold the event recorder to his/her chest, press the "record" button, and record up to a 45-second event.
The event recorder will be capable of storing up to six, 45-second recordings. The patient will then either take the recorder to his or her physician for review, or transmit the data to a subscription-based 24-hour monitoring center where it can be immediately evaluated by a qualified ECG technician, cardiac nurse or cardiologist.

This card will allow patients to effectively monitor their hearts anytime, anyplace, without the necessity of a prescription or other physician intervention. This, in turn, will lead to additional care and may lead to earlier intervention and other preventative measures for cardiovascular disease - the most costly of all diseases nationwide with annual expenditures approaching $400,000,000 spent across the country.

Fidelity 300
Signalife believes that ambulatory electrocardiography can be advanced through the application of its patented technology. Fidelity 300, under development, is a portable Holter recorder that provides superior data quality and capabilities for up to 30 days of recording. The American College of Cardiology and American Heart Association recognize the importance of Ambulatory Electrocardiography (AECG) and provides Guidelines on the use of AECG to aid clinical decision making. Accurate electrocardiographic interpretation assumes that technical standards are adhered to during the acquisition and recording of ECG signal in the field. It is well known that artifacts may result in an incorrect diagnosis of arrhythmias and may lead to unnecessary interventions and treatment [13].

Signalife’s patented technology provides a unique platform that allows for high-fidelity recording in harsh environments. Signalife is striving to become the gold standard for collecting ECG data in ambulatory environment.

Fidelity 400
The Signalife Fidelity 400 Intra-Cardiac Monitor, under development, applies Signalife's award-winning proprietary physiological signal acquisition and amplification technology to record intracardiac signals procured from intracardiac catheter. An intracardiac catheter is a flexible tube that is inserted through a vein in the leg and fed into the heart. The catheter is equipped with electrodes which allow recording of signals from within the heart. These signals are transmitted to a monitor allowing physicians to evaluate various cardiac functions, including arrhythmias. These readings are beneficial in that they measure signals directly from the heart, as opposed to signals read from the surface of the body. The main objective and benefit of the novel system is to offer a technology that overcomes problems presently associated with recordings of surface ECGs and intracardiac signals during electrophysiological studies.

The Future
As Signalife continue to take the correct approach in noninvasive detection of the presence of heart disease it continues to improve its system. While focusing first and for most on collecting accurate data that gives you the most accurate starting point. Only then can you make the proper diagnosis and treatment plan. Signalife is continuing to properly develop lifesaving systems and integrate systems such as auto-interpretation, electrical axis determination and interval measurement. Inpatient telemetry systems include; trending reporting for heart rate, ST segments, etc, ST and HR alarms, and integration with hemodynamic monitoring equipment. All of which can be extremely beneficial if used with accurate data.

Conclusion
One of the basic doctrines of healthcare states that if a tool exists that can improve the level of care provided it must be used, so one would expect mandates which require this type of system will eventually come along. Those that wish to uphold the highest standards of care should begin using this system as soon as they hear of it, not because they have to but because it’s the right thing to do.

Based on laboratory, clinical, and field evaluations, Signalife technology can be used to properly diagnose more precise changes in the electrical signal of the heart which lead to the detection of known cardiovascular abnormalities. Signalife’s technology is the only choice for recording a consistently accurate ECG. Never sacrifice fidelity when it comes to the heart.
References:

1. Robert L. Lux, Journal of Electrocardiology, Vol. 33 Supplement, 2000.
2. David Buckles et al, Advances in Ambulatory Monitoring: Regulatory Considerations,
International Society for Computerized Electrocardiology ’04 Abstract Book, Pg. 15,
April 2004.
3. Paul Kligfield and Peter M. Okin, Prevalence and Clinical Implications of Improper
Filter Settings in Routine Electrocardiography, Journal of Cardiology, Vol. 99, 2007,
711-713.
4. American Hearth Association, http://circ.ahajournals.org/cgi/reprint/115/10/1306.
5. Budimir S. Drakulic et al, Electrocardiograph High Pass Frequency Response Revisited,
presented at the ISCE 30th Annual Conference poster session, Lihue Kauai, HI, April 12-
17, 2005.
6. ACC/AHA, Journal of American College of Cardiology, Vol. 34, No. 3, September
1999:912-48.
7. Marko N. Kostic et al, Evaluation of Novel ECG Signal Processing on Quantification of
Transient Ischemia and Baseline Wander Suppression, presented at the 29th International
Conference of the IEEE Engineering in Medicine and Biology Society in Lyon, France,
August 2007.
8. Signalife, Inc., Appendix A – DIVA Recordings, Signalife Technology, November 2007.
9. Signalife, Inc., Appendix B – Cathlab Recordings, Signalife Technology, November
2007.
10. Mauricio Arruda et al, A Novel Portable Wireless Multi-channel ECG and Intracardiac
Recording System, presented at the 2006 Heart and Rhythm Society Conference in
Boston, Massachusetts.
11. Signalife, Inc., Appendix C – AHA Demonstration, Signalife Technology, November
2007.
12. Haran Burri, et al, Simulation of Anteroseptal Myocardial Infarction by
Electrocardiographic Filters, Journal of Cardiology, Vol 39, 2006, 253-258.
13. ACC/AHA, Guidelines for Ambulatory Electrocardiography, Journal of American
College of Cardiology, Vol.34, No.3, 1999, 912-48

http://www.executivehm.com/currentissue/article.asp?art=272831&issue=241


a link to this article was posted on the SGN website 4/11/08

http://www.signalife.com/Pages/News2008.asp

[TheRaveninexile]

Making a Difference

Extending electrocardiography into new applications will reduce the burden of heart disease and extend the quality-of-life to patients suffering from heart disease.

By Lowell T. Harmison

Signalife’s patented technology provides a unique platform for biomedical signal acquisition, classification and evaluation of treatment for cardiovascular diseases. Original signal processing technology was developed by Signalife’s Chief Technology Officer in the early 1990s for the US Air Force and NASA to enable recording of pilots’ brainwaves in the harsh environment of the jet airplane cockpits. The technology was further improved and used in sleep recorder devices that would enable home-based sleep studies. Signalife’s R&D team adjusted certain parameters of this technology to provide clinical-quality electrocardiographic recordings in ambulatory, exercise stress testing, and ultimately continuous 24/7 monitoring. In April of 2004, a group of authors from the FDA that reviewed Signalife’s Fidelity 100 510(k) submission presented a position paper at the 29th Annual Conference of the International Society for Computerized Electrocardiology (ISCE) describing a new ambulatory recording system, i.e. the Signalife system, that can become another source for diagnostic-quality 12-lead ECG records on par with other modalities such as resting ECG and exercise stress testing.

The field of electrocardiography has seen many changes in application to better understand the heart. However, very little has been done to improve the basic core-industry technology that allows you to get a more accurate and clearer signal reflecting what is actually going on in the heart.

The Signalife technology makes a sea change in signal quality that truly represents what is occurring in your heart muscle. It does this by eliminating noise, motion artifact, signal filtering and other core normal elements altering the quality of the echocardiogram. Further, these basic improvements allow for evaluation of your heart under ambulatory conditions as well as a more definitive assessment of your heart under defined stress testing.

This is truly a giant step forward for the practice of medicine and its ability to diagnose and treat heart disease. In addition, it provides a new world for collecting previously uncollectible valuable research data and information concerning drug therapies and other treatments for cardiac and cardiovascular conditions.

Furthermore, the technology allows for 12 lead diagnostic assessments of patients from the point of a 911 pickup for more rapid and proper application of life saving therapies to begin before reaching the hospital, to providing more efficient continuous monitoring from the hospital door through treatment and patient discharge. It also provides for the first time monitoring of high-risk cardiac patients post hospital discharge. These are the characteristics and functions that set the Signalife electrocardiographic technology apart from all others in this field.

Signalife Fidelity 100 makes a difference in ECG diagnostic monitoring across the full spectrum of heart disease under practically every environment and in every category, i.e.:

cardiac treatment modalities including surgery

drug regimens

emergency medicine and acute care

cardiac/cardiovascular screening as well as all ambulatory applications

Clearly, what counts are the differences made in understanding heart disease and how it should be treated. If the difference is dramatic and clear, it alters our understanding of the disease and the prescription/recommendations for the patient. This will save lives and allow physicians to deliver improved patient care.

No company makes a product that will do what the Signalife products do. This is the core contribution that extends electrocardiography into new applications as well as improving existing applications for better heart monitoring and care to reduce the burden of heart disease and extend quality-of-life to so many suffering from heart disease.

Cardiovascular Disease

64 million Americans have cardiovascular disease (CVD) spending $393.5 billion annually

CVD is a primary or contributing cause for more than 1.4 million deaths in America each year

CVD mortality rate equates to about 60 percent of ‘total mortality’

Percentage breakdown of deaths from cardiovascular diseases (US: 2004)

Source: NCHS and NHLBI

Trends in Cardiovascular Operations and Procedures (US: 1979-2004)

Source: NCHS and NHLBI (Note: Inpatient procedures only)



http://www.executivehm.com/currentissue/article.asp?art=272877&issue=241

a link to this article was posted on the SGN website 4/11/08

http://www.signalife.com/Pages/News2008.asp

[TheRaveninexile]

How many times in recent memory have you seen headlines reading, "Health Care Sector a Safe Bet" or how about "Looking for a new Career? Considering Nursing"?

Right now the health care sector is being touted as one of the best plans of attack for folks looking for a sure bet. The boomers are all retiring and the health care sector is expected to continue growing even during a down turn in the economy. Actually it has no choice but to continue to grow due to our rapidly aging demographic. Face it, we aren't getting any younger as a society currently.

So here we have a company that has a really great product that fills a pretty big need in the cardiac monitoring arena, has what could pretty much be considered disruptive technology (I really despise this overly used term) and in what has been a technologically stagnant funk for the last 2 decades. This is all happening in a sector that should see some decent growth over the coming years. The health care sector has outperformed the S&P in almost every recession. The sector has preformed poorly over the last few years, it's been shunned but the money is going to start moving back in this direction very soon.

Good technology, good product, decent company and in an ever increasingly attractive sector.

What is not to like?

[TheRaveninexile]

*lol* I've been watching this company for well over a year. I knew it was going to take a while for them to really get somewhere and I had concerns as to whether or not they'd actually be able to generate sales. I knew the technology was great but there are many companies with great technology that die in the water because they can't make any inroads in the market.

Now that SGN is booking some significant orders that to me says that they're ready to compete with the likes of the major ECG equipment manufacturers. My guess is that tomorrow's webcast is going to have some pretty interesting forecasts, that this thing is going to really start to move up and to a higher base.

[J-RO]

SGN Chart ~> Looking Pu'rdy Good

[ChangeDirector]

You have all that information, have you ever posted on this board before? I don't see anything back far as December.

You could have at least let me know yesterday!:)

[TheRaveninexile]

The more people exposed to the product the more investors we're going to see. This upcoming webcast could cause a significant stir if their sales projections are good.

Let me tell you, EKG technology has been virtually unchanged in the last 20 years. The quality you get now is the same as it's been. From professional experience having worked with them for 15 years, they're a pain in the butt and they are pretty crude determiners of cardiovascular disease and damage. Not only that but they are cumbersome and uncomfortable for the patient. They require a lot of time to keep them hooked up to the patient and the readings are fraught with artifact. It's not funny when a guy brushing his teeth looks like V-tach on the monitor because of the electrical interference created by motion.

What this company has is something that we've needed for a long time. Because it will save the hospitals time (manpower to keep these things working) it will also boost the diagnostic capabilities of ECG's. This creates more business by detecting disease better and earlier. More patients diagnosed means further investigation and surgical intervention. It's a business booster. More people take drugs to lower their blood pressures and reduce their cholesterol early. It's a win, win situation for hospitals.

This company is going to sell a LOT of product. I can see it being the replacement standard for all hospitals and clinics. When the equipment contract runs out a lot of places will be making the switch.

[ChangeDirector]

SGN up 20% today and new news, no postings? Scary.

[TechKim]

Signalife Announces Webcast
Monday April 7, 9:00 am ET


GREENVILLE, S.C., April 7, 2008 /PRNewswire-FirstCall/ -- Signalife, Inc. (AMEX: SGN - News) has confirmed that it has filed its form 10-KSB, and the company's Chairman and Chief Executive Officer, Dr. Lowell T. Harmison, has scheduled a webcast on April 14, 2008, at 10:00 a.m. EST.


Dr. Harmison stated: "Now that Signalife has closed filing the company's form 10-KSB and the Company is manufacturing and shipping product, I am pleased to provide direction on new contracts, pending orders and production, various product initiatives (from the Fidelity 100 to the prospective industry-wide application of the Fidelity 1000 module), and the Athletes For Life partnership, as well as such issues as the Company's immediate, positive financial prospects as well as several other initiatives that have now been completed. The webcast will be broadcast from a studio and will be attended by representatives of Athletes for Life Foundation and selected invited members of the business press. To the extent time permits, I will answer questions following my presentation. I urge all persons following the company to view the webcast."

You may access the webcast at http://www.videonewswire.com/event.asp?id=47313 and will have the opportunity to submit written questions over the internet. You may also view or review the webcast for a 12-month period at the same website address (please allow several hours for Signalife to effectuate this archival link). All individuals viewing the original webcast or any replay are reminded that the webcast is copyrighted by the company and cannot be recorded or rebroadcast without the company's express written consent.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward- looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.



SOURCE Signalife, Inc.
-0- 04/07/2008

/CONTACT: Dr. Lowell T. Harmison, CEO of Signalife, Inc., [phone]/


/First Call Analyst: /
/FCMN Contact: [e-mail] /
/Web site: http://www.signalife.com
http://www.videonewswire.com/event.asp?id=47313 /
(SGN)

CO: Signalife, Inc.
ST: South Carolina
IN: HEA MTC SPT
SU: CCA

SB-FK
-- NYM052 --
0305 04/07/2008 09:00 EDT http://www.prnewswire.com




--------------------------------------------------------------------------------
Source: PR Newswire

[TechKim]

Signalife Wins More Business; Actively Shipping Orders
Tuesday March 25, 9:30 am ET


LOS ANGELES, March 25 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that it has been and continues to ship orders under what Dr. Harmison calls an "efficient production line at its manufacturing facility." Additionally, the Company has received an additional $7.5 million in Fidelity 100 device delivery orders in the month of March, 2008, which the company intends to fill during the next two quarters. The Company said it may fill these orders sooner.



Dr. Harmison stated: "I am very comfortable with our production line capabilities in terms of their immediate capacity - which will now ramp up to a minimum of 125 production model Fidelity 100 devices per month and grow from there. This capability will be expanded significantly to meet growing demand.

The Company also added that it is continuing discussions with its European and Asian partners (and prospective ones), and Dr. Harmison "anticipates that these opportunities will bear fruit ten days from today. I am pleased to be able to provide this update."

In finishing, Dr. Harmison stated: "The reach of the Frost & Sullivan organization into Asia -and our devices having won the Frost technology awards in two out of three years - has been a significant marketing tool whose uses are obvious and are compelling."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

The Company has moved its corporate headquarters back to Los Angeles, California following the termination of prior management who desired the Greenville, South Carolina location and based their prospective success on that location - which never came to fruition. The Company continues to consult with several employees and professionals in the Greenville area.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the Signalife devices, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[manysevens]

SGN Annotated Chart

[TechKim]

AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance
Thursday March 20, 2:30 pm ET


GREENVILLE, S.C., March 20 /PRNewswire-FirstCall/ -- On January 7, 2008, Signalife received a deficiency letter from the American Stock Exchange ("AMEX") pursuant to which it advised that Signalife would need to comply with the $6 million stockholders' equity threshold required for continued listing under AMEX Rules 1003(a)(iii). This notification was triggered by the decline of Signalife's market capitalization to less than $50 million, which previously exempted Signalife from meeting the minimum stockholders' equity requirement. Pursuant to the letter, Signalife submitted to AMEX for its review and acceptance a plan to bring the company into compliance with the aforesaid stockholders' equity requirement. On March 20, 2008, AMEX notified Signalife that it accepted the company's plan of compliance and granted the company an extension until May 7, 2009 to regain compliance with the aforesaid stockholders' equity requirement. Signalife will be subject to periodic review by AMEX Staff during this extension period. Failure to make progress consistent with the plan or to otherwise regain compliance with the aforesaid stockholders' equity requirement by the end of the extension period could result in the company being delisted from AMEX.


About Signalife, Inc.

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife, Inc. is the recipient of the Frost & Sullivan Technological Innovation Award for 2006 and 2008.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. For example, no assurance can be given that Signalife will attain the results set forth in the plan or otherwise satisfy AMEX's continued listing requirements, or that Signalife's common stock will continue to trade on AMEX. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

Signalife Sees Accretive Purchase and Financial Commitments
Monday March 17, 9:30 am ET


LOS ANGELES, March 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced earlier today that it has received several formal purchase and financial commitments with respect to acquisitions of the Company's technology licenses, devices and services. These commitments have come internationally, including in Japan, other parts of Asia and Europe, as well as domestically.


Dr. Harmison, the Company's President and CEO, stated: "I anticipate closing these transactions in the upcoming two to four weeks, which comprise significant business for the Company. With the experiential base developed during my tenure regarding the ECG data generated from the usage of our technologies -- not only by health care providers but also through numerous Athletes for Life-sponsored mobile health care screenings -- there are now numerous additional revenue streams that have naturally become available to the Company. Indeed, physicians have provided me with a variety of data and information following very successful screenings this past weekend on the Athletes for Life Mobile Health Center in Temecula, California. With this kind of data garnered from real patients in the field, the foundation for the expansion of our life-saving devices becomes stronger every day."

The Company did not state the exact amount of business contemplated by these developments, and it cautioned that there is no certainty that any of the transactions will close as contemplated -- or at all.

[TechKim]

Signalife Provides Corporate Update
Tuesday February 26, 9:00 am ET


LOS ANGELES, Feb. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) -- through its President and Chief Executive Officer Dr. Lowell Harmison -- has just issued the following corporate update.


Signalife Products

Fidelity 1000 -- New Product

The Company has developed a modular solution to evaluate existing ECG devices by development of a module -- called the Fidelity 1000 -- that would effectively enable testing of the fidelity of ECG devices. Dr. Harmison commented: "We would like to provide scientific evidence regarding the ability of our devices to reproduce known ECG signals with the highest fidelity. We are building a database of important ECG wave shapes that can be used together with other publicly available databases for evaluation of our technology but also of other devices on the market." The Fidelity 1000 is expected to support and expand Signalife's footprint into the cardiovascular disease marketplace worldwide. Further, Dr. Harmison commented: "Much like the urgency of Y2K eight years ago, there is a movement toward assuring that all ECG machines of every kind will come into compliance with clinical standards issued by the AHA. Signalife's technologies are uniquely suited to do that, and the Company is moving to solve the problem."

Fidelity 100 -- Original 12-Lead Award Winning Product

The Company has completed upgrades and is now manufacturing upgraded units for outstanding orders for its FDA-cleared Fidelity 100. These upgrades have undergone vigorous evaluation and testing and do not modify the device. "We have made our device more congruent with the objectives across the health care industry, and expect to get even more attention in the marketplace than today."

Fidelity 200 -- Unique Non-Prescription Credit Card Heart Monitor

For the Fidelity 200, the Company has chosen its last group of product manufacturers, the schematics have been completed, the pre-launch has been started and many key steps will be completed in the next 30 days as the Company now enters final negotiations to acquire its call center to launch the HeartTempo(TM) Card, otherwise known as the Fidelity 200.

Fidelity 350 -- New Product

Signalife has developed a digital, mini-Holter monitor that incorporates the award-winning technologies of the Company. This device has the capability to record for 30 days, work on a fully wireless network, and be reduced to the size of a very small pager. In an era of socialized health care across Europe -- and a constant pressure of cost reduction in the United States -- this is a device "whose time has come" according to Dr. Harmison. The product is beyond prototype and is expected to be submitted to the FDA shortly.

Fidelity 400 -- Intra-Cardiac Monitor

Developed in conjunction with Cleveland Clinic, this important device -- unveiled at the Heart Rhythm Society Convention -- is in final performance evaluation and testing and is expected to be submitted to the FDA later this year. It is anticipated that this device will enable the acquisitions of new data and development of new approaches to electrophysiological studies of the heart that are performed in electrophysiological labs around the world.

Financing Partnership

Subsequent to entering into the $100 million contractual relationship with the Yorkville group of companies, Signalife has accessed less than $500,000 (five hundred thousand dollars) of its $100,000,000 line of credit. As Dr. Harmison remarked: "We are pleased with our relationship with Yorkville. The Yorkville companies have done everything according to the letter of the contract, and have been very supportive of Signalife. We anticipate accessing the Yorkville equity line from time to time, and only then will additional shares be issued to Yorkville. The Yorkville relationship is a breath of fresh air -- Yorkville is predictable, honorable and is very supportive of the Company's initiatives as reflected by its $100,000,000 contractual commitment and its staunch support of that commitment. Yorkville's staff has a keen level of sophistication regarding the massive worldwide markets for the Signalife technologies, and its support is important and appreciated by Signalife and its many partners." The Company intends to continue to utilize Yorkville as an investment bank as well as with regard to its existing contractual commitment on the $100 million SEDA.

Signalife Markets

In addition to the North American markets for Signalife products, the world is -- as Dr. Harmison remarks -- "becoming smaller." The CEO continued: "Not only have we begun manufacturing and delivery schedules for existing orders, but the Company has vigorously pursued and established product demand in Singapore, China, Indonesia, Western Europe, Eastern Europe, Korea and the United Kingdom." The Company believes that the worldwide markets are "explosive" (in the words of Dr. Harmison) and that this will be demonstrated in "the short, medium and long term," the CEO added.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

Signalife & Athletes Foundation Complete Second Mobile Health Screening
Tuesday February 19, 1:00 pm ET


LOS ANGELES, Feb. 19 /PRNewswire-FirstCall/ -- Athletes for Life Foundation (a District of Columbia Not for Profit Foundation) and Signalife (Amex: SGN - News) have just completed their second mobile health screening at the Arabian Horse Show in Scottsdale, Arizona -- the largest such event in the world, at its 35th anniversary.


Physicians and health care institutions from around the area donated their time to care for the patients, conducting dozens of screenings utilizing Signalife's award-winning Fidelity 100 ECG monitor. The screenings were conducted free of charge to the patients.

Willie Gault, the Foundation's founder, commented: "During the weekend, doctors reported that they had detected pathology in certain patients that was normally difficult or impossible to identify. Also, certain patients remarked to me that they were previously advised to undergo thousands of dollars of heart tests by their physicians -- but were given a clean bill of heart health at the event by the attending physicians. This is why I started the Foundation: To create some certainty in heart health, and to level the playing field from the perspective of cost and access for all persons. I would like to thank all those who donated their time to conduct these screenings and evaluations."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

About Athletes for Life Foundation

Athletes for Life Foundation is a District of Columbia Non-Profit Foundation containing dozens of famous role models and athletes who are tired of having their friends die at early ages -- or have invasive heart procedures -- when there may be a better way to treat the disease and to save lives. The Foundation is committed to -- and does in fact -- bring new technologies to healthcare, it brings life mobiles to communities so that health care comes to the masses and not visa versa, it provides foundational support for health care facilities and hospitals, and "levels the playing field" for all demographic groups of cultures through competent health care facilities and education with the role models and athletes who have made our lives unique in decades of professional sports.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[alien_scones]

spam fax

prepare for P&D

[TechKim]

Signalife Establishes Signalcare Division
Thursday February 14, 6:00 am ET


LOS ANGELES, Feb. 14 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has established a division focused on developing, acquiring and/or testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.


From experience gained and relationships developed through the deployment of its award-winning Fidelity 100 Heart Monitor - including extensive utilization of the Fidelity 100 at this year's Super Bowl in Glendale, Arizona -- the Company has already learned significant details regarding the relationship between earlier and more accurate cardiovascular monitoring, on the one hand, and effective cardiovascular treatment-oriented technologies, on the other hand.

Dr. Lowell Harmison, the Company's President and Chief Executive Officer, commented that "more effective heart monitoring can be used to validate or invalidate technologies that, before now, were unable to be properly vetted. Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies."

The Company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
Wednesday January 30, 9:10 am ET


LOS ANGELES, Jan. 30 /PRNewswire-FirstCall/ -- Athletes for Life Foundation, a 501(c)(3) non-profit foundation duly incorporated in the District of Columbia ("Foundation"), and Signalife (Amex: SGN - News), have just dispatched to Glendale, Arizona's Super Bowl site the first mobile health center owned by the Foundation. Each mobile health center is named after a professional athlete (across all sports) -- or their families or estates -- who are a part of the cause of eradicating sudden cardiac death and late stage cardiovascular disease. The Ford truck, and 48' attached health center, was sent to Glendale after being dedicated to pro-football great Reggie White -- known as a great and compassionate man, and winner, and one of the all-time great defensive linemen in football history.


Physician groups and health care experts from surrounding states will be stationed at the center to conduct health screenings for all members of the public. The public is invited to attend, and the physicians have indicated they will make every effort to provide screenings to all those in need. When the physicians deem it appropriate, their evaluations will include ambulatory heart screenings utilizing the award-winning Fidelity 100 ambulatory ECG monitor. Signalife believes this to be the only ambulatory ECG monitor capable of detecting subtle shifts and changes in a patient's ECG that are believed to be important to the evaluation of a person's heart health.

The Foundation's Founder, Willie Gault, commented: "I cannot begin to put into words how grateful I am for all of our sponsors who have made these efforts possible. Reggie White was a great man who I knew as a dear friend for many years -- going back to our days together at the University of Tennessee. For a man with all the goodness of Mr. White as a person, and all the amazing things he did as a professional athlete, for some reason our health care system was unable to give his family Reggie's full life. From my experience, Reggie White may have been the greatest to ever play professional football. At the time of his retirement, White was the NFL's all-time sacks leader with 198. In addition to being enshrined in the Hall of Fame, three teams retired White's number 92 jersey. To have our flagship mobile health center dedicated to my friend and legend Reggie White is an honor indeed."

Mr. Gault continued: "I must express my most sincere thanks to Sarah White and the Reggie White Estate for their support of the Foundation. On behalf of the Foundation's more than 65 Members, I would like to say to Mrs. White this: 'It is not all in vain. We will never forget. The system will change, and the Foundation will not take no for an answer. It begins this week. I offer my sincere thanks.'"

Dr. Lowell Harmison, President and Chief Executive Officer of Signalife, Inc. -- maker of the Fidelity 100 -- continued: "For a man as impressive, both on off the playing field, as Reggie White to be taken from society and from his family at such a young age -- from a completely solvable and preventable heart condition -- should be an abomination to our modern society. According to the Mecklenburg County Medical Examiner's Office, the most likely cause of death was cardiac and pulmonary sarcoiodosis. This led to a fatal cardiac arrhythmia. This is, to me, an outrage. For every person as unfortunate as Mr. White, there are countless people who are silent to us who have experienced the same fate."

Dr. Harmison -- the former Principal Deputy of the United States Department of Health Services under the Reagan Administration, and author of the book Zeroing In On Your Heart, continued: "The level playing field starts today."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

About Athletes for Life Foundation

Athletes for Life Foundation is a Non-Profit Foundation containing dozens of famous role models and athletes who are tired of having their friends die at early ages -- or have invasive heart procedures -- when there is no reason for our advanced society to be so backward. The Foundation is committed to - and does in fact - bring new technologies to healthcare, it brings life mobiles to communities so that health care comes to the masses and not visa versa, it provides foundational support for health care facilities and hospitals, and "levels the playing field" for all demographic groups of cultures through competent health care facilities and education with the role models and athletes who have made our lives unique in decades of professional sports.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

NFL Hall of Fame Legend Michael Irvin Joins Signalife-AFL Cardiovascular Protection Team
Wednesday January 23, 9:20 am ET


LOS ANGELES, Jan. 23 /PRNewswire-FirstCall/ -- NFL Hall of Fame wide receiver and broadcaster, Michael Irvin has joined the unparalleled list of current and former celebrities and professional athletes to have provided their names and likenesses to support the deployment of Athletes for Life's ("AFL's) network - including the revolutionary Signalife technologies - to eradicate late-stage cardiovascular disease.


Mr. Irvin had an unparalleled career and was the ultimate "possession receiver" who was also a pure - undeniable -- game breaker. He is regarded as one of the most successful wide receivers in the history of professional football, winning three Super Bowls, and nicknamed the "playmaker."

Irvin finished his career with 750 receptions (10th all-time) for 11,904 yards (9th all-time) and 65 touchdowns. His 47 100-yard receiving games remains the third most in NFL history, behind Hall of Famers Jerry Rice (65) and Don Maynard (50). Mr. Rice is also an Athletes for Life member for purposes of ridding society of the same fate brought about by late-stage cardiovascular disease.

Lowell Harmison commented: "We cannot level the playing field for all people of all demographic groups without having legendary superstars like Mr. Irvin who see the vision like we do. Only with early intervention and effective, accurate care can the problem of cardiovascular disease be effectively dealt with. We are extremely excited that Mr. Irvin sees the vision and the importance of this project to his friends, family and those to whom he is a role model."

Willie Gault, AFL's founder, stated that "it is rare to have one of my personal heroes stand alongside me to fight this disease. It is an easy equation, involving early detection and effective care. As athletes, we know that the heart must be at stress in order to accurately determine and predict its likely reaction to the challenges created throughout a patient's lifetime. I am so proud and encouraged by having my friend Michael Irvin join the overwhelming number of athletes who have simply decided that they are going to make the difference."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

About Athletes for Life

Athletes for Life is a Non-Profit Foundation containing dozens of famous role models and athletes who are tired of having their friends die at early ages - or have invasive heart procedures - when there is no reason for our advanced society to be so backward. AFL is committed to - and does in fact - bring new technologies to healthcare, it brings life mobiles to communities so that health care comes to the masses and not visa versa, it provides foundational support for health care facilities and hospitals, and "levels the playing field" for all demographic groups of cultures through competent health care facilities and education with the role models and athletes who have made our lives unique in decades of professional sports.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

Ford Motor Company Sponsors Athletes for Life Foundation
Tuesday January 22, 9:20 am ET


LOS ANGELES, Jan. 22 /PRNewswire-FirstCall/ -- Athletes for Life Foundation ("AFL"), representing such legends as Jimmy Brown, Joe Theismann, Rick Barry, Anthony Munoz -- and dozens of other Hall of Fame athletes from every area of sports and all demographics -- has announced that it has reached a sponsorship accord with Ford Motor Company (NYSE: F - News) with respect to AFL's corporate charter of eradicating late-stage cardiovascular disease. The details of the sponsorship accord have not been disclosed, and -- as well -- are private as between the two corporations.


Willie Gault -- AFL's Founder -- commented: "We are extremely pleased and excited that the legendary Ford Motor Company has had the vision and foresight to assist in AFL's furious quest to change the way cardiovascular disease is monitored and treated. To have perhaps America's most legendary company, Ford, assisting the legends that make-up Athletes for Life is quite gratifying indeed. With the use of the Signalife technologies, we will be able to make the time for change now. The public is advised to keep a close eye on upcoming press releases regarding initial and upcoming events as AFL rolls out its health care machine at which point we will level the playing field for the benefit of our sponsors, constituents and supporters."

About Ford Motor Company

Ford Motor Company and its subsidiaries design, develop, manufacture, and service cars, trucks, and parts worldwide. The company operates through two sectors: Automotive and Financial Services. The Automotive sector sells cars, trucks, and parts under Ford, Mercury, Lincoln, Volvo, Land Rover, Jaguar, and Aston Martin brand names. This sector markets its products through retail dealers in North America, and through distributors and dealers outside of North America. In addition, it sells cars and trucks to dealers for sale to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. This sector also provides a range of after-the-sale vehicle services and products, maintenance and light repair, heavy repair, collision, vehicle accessories, and extended service warranty. The Finance Services sector offers various automotive financing products to and through automotive dealers worldwide. It offers retail financing, wholesale financing, and other financing, such as making loans to dealers for working capital, improvements to dealership facilities, and the acquisition and refinancing of dealership real estate. This sector services the finance receivables and leases that it originates and purchases, makes loans to affiliates, purchases receivables, and provides insurance services related to its financing programs. The company was founded in 1903 and is based in Dearborn, Michigan.

About Athletes for Life Foundation

Athletes for Life is a Non-Profit Foundation containing dozens of famous role models and athletes who are tired of having their friends die at early ages -- or have invasive heart procedures -- when there is no reason for our advanced society to be so backward. AFL is committed to -- and does in fact - - bring new technologies to healthcare, it brings life mobiles to communities so that health care comes to the masses and not visa versa, it provides foundational support for health care facilities and hospitals, and "levels the playing field" for all demographic groups of cultures through competent health care facilities and education with the role models and athletes who have made our lives unique in decades of professional sports.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders' Equity Requirement
Monday January 14, 4:57 pm ET


GREENVILLE, S.C., Jan. 14 /PRNewswire-FirstCall/ -- On January 7, 2008, The American Stock Exchange ("AMEX") issued a deficiency letter to Signalife pursuant to which it advised Signalife that it would need to comply with the $6 million stockholders' equity threshold required for continued listing under AMEX Rules 1003(a)(iii). This notification was triggered by the recent decline of Signalife's market capitalization to less than $50 million, which previously exempted Signalife from meeting the minimum stockholders' equity requirement. Pursuant to the letter, Signalife will be required to submit to AMEX by February 6, 2008 for its review and acceptance a plan to bring the company into compliance with the aforesaid stockholders' equity requirement within a sixteen month period or by such earlier date as AMEX may deem reasonable. Signalife is presently preparing a plan to submit to AMEX to address the stockholders' equity matter.


The deficiency letter is the second instance in which AMEX noted the decline in Signalife's market price to below the $50 million level. Signalife received the earlier deficiency letter from AMEX in June 2007, pursuant to which Signalife provided a plan to AMEX which was not rejected by AMEX and which Signalife will amend and resubmit in response to this latest notice. This earlier deficiency was cured in October 2007 as a result of the return of Signalife's market capitalization to above $50 million.

No guarantee can be given that AMEX will accept the plan or that Signalife will be able to so increase its stockholders' equity to the $6 million threshold within the period stipulated by AMEX, either of which would lead to a delisting of Signalife's common shares from the AMEX market. If Signalife's market capitalization were to again return to levels above $50 million, and were maintained at that level, and if the Company was otherwise in compliance with all AMEX rules, then the new plan to be submitted will not need to be implemented.

About Signalife, Inc.

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife, Inc. is the recipient of the Frost & Sullivan Technological Innovation Award for 2006.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. For example, no assurance can be given that the AMEX will approve Signalife's proposed plan, or that Signalife's common stock will continue to trade on AMEX. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

I agree with the potential which has not been revealed. The recent sales and end result marketing from the draw down of alloted credit has not been published.

[jonesieatl]

SGN: SB-2

This one hasn't done all that badly, but I think they are fairly new to Cornell, I have them in the table (see Cornell/Yorkville board linked below) dated 8/6/07.

Some shares hitting the market soon?

http://www.sec.gov/Archives/edgar/data/810365/000081036508000002/sgnsb2foryaglobalsedav5final.htm

"This prospectus relates to the offer and sale by one of our shareholders, YA Global Investments, L.P. (“YA Global Investments”) and/or certain of its pledgees, donees, transferees and other successors (collectively, the “selling shareholders”), during the period in which the registration statement containing this prospectus is effective, of up to 9,229,373 common shares that YA Global Investments may prospectively purchase from Signalife under a Standby Equity Distribution Agreement dated August 6, 2007 with YA Global Investments (the “Standby Equity Distribution Agreement”)."

[[[[

[TechKim]

Signalife Presence at XIII World Congress on Cardiac Pacing and
Electrophysiology


STUDIO CITY, CA, December 3, 2007 -- Signalife, Inc. (Amex: SGN - News)
has announced its presence at the XIII World Congress on Cardiac Pacing
and Electrophysiology to be held December 2-6, 2007 in Rome, Italy. At
the Congress, Dr. Muricio Arruda, who has been testing Signalife's
wireless Fidelity 400 Intracardiac Monitor at the Electrophysiology
Laboratories of the Cleveland Clinic Heart Center, will present a
prototoype of the Fidelity 400 Intracardiac Monitor to selected
participants. The Signalife Fidelity 400 Intracardiac Monitor applies
Signalife's award-winning proprietary physiological signal acquisition and
amplification technology to read intracardiac signals procured from
intracardiac catheter products. An intracardiac catheter is a flexible
tube that is inserted through a vein in the leg and fed into the heart.
The catheter is equipped with electrodes which allows the signal to be
recorded within the heart, and the catheter data is transmitted to a
monitor, which allows the physician to evaluate cardiac function,
including arrhythmia, or irregular heartbeat. These readings are
beneficial in that they measure signals directly from the heart, as
opposed to signals read from the surface of the body as is typical in the
ordinary application of heart monitors.
The mission of the World Congress of Cardiac Pacing and Electrophysiology
is to provide an education forum, underlining evidence-based clinical
practices in the field of arrhythmology for clinical cardiologists and
electrophysiologists. The Congress will also highlight the latest and
most advanced topics in invasive electrophysiology and cardiac pacing,
giving leading electrophysiologists the opportunity to demonstrate and
discuss new diagnostic and therapeutic strategies.
Dr. Arruda, a faculty member of the XIII World Congress, stated: "I am
very happy and impressed with the progress made by the Signalife research
& development team on the Fidelity 400 multi- channel, wireless ECG/IC
system from the initial results presented at the 2006 Heart and Rhythm
Society Conference. The main objective and benefit of the novel system is
to offer a technology that overcomes problems presently associated with
recordings of surface ECG and intracardiac signals during
electrophysiological studies".
Dr. Budimir Drakulic, Signalife's Chief Technology Officer, stated: "We
have applied Signalife's patented signal processing technology to
intracardiac signals with the same success realized with ambulatory ECG
recordings and are looking forward to further development of this
technology. We intend to file this one-of-a-kind intra-cardiac monitor
for FDA approval shortly."
Dr Lowell Harmison, Signalife's President, states that "this technology
application will allow us to get new data concerning a host of
electrophysiological changes in the heart that were impossible to be
obtained before. Our electrocardiography technology is opening new
opportunities for medical research and clinical findings based on getting
a more accurate and definitive ECG signal in the catheterization lab and
surgery as well as under conditions of stress and a spectrum of ambulatory
conditions. It is becoming a powerful new tool for cardiac monitoring and
for improved cardiac care."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and
detection of disease through continuous biomedical signal monitoring.
Signalife uses its patented signal technology to design and develop
medical devices that simplify and reduce the costs of diagnostic testing
and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the
symbol SGN. The website for the company is http://www.Signalife.com. Clear
Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-
looking" statements. Forward-looking statements involve known and unknown
risks, which may cause Signalife's actual results in the future to differ
materially from expected results. Factors which could cause or contribute
to such differences include, but are not limited to, failure to complete
the development and introduction of heart monitoring and other biomedical
devices incorporating Signalife's technology, failure to obtain federal or
state regulatory approvals governing heart monitoring and other biomedical
devices incorporating Signalife's technology, inability to obtain
physician, patient or insurance acceptance of for heart monitoring and
other biomedical incorporating Signalife's technology, and the
unavailability of financing to complete management's plans and objectives,
including the development of heart monitoring and other biomedical
incorporating Signalife's technology. These risks are qualified in their
entirety by cautionary language and risk factors set forth and to be
further described in Signalife's filings with the Securities and Exchange
Commission.

[TechKim]

Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
Monday November 26, 9:20 am ET


LOS ANGELES, Nov. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has received FDA 510(k) clearance to market and sell - without prescription - its ambulatory event recorder throughout the United States. This device, which Signalife will market as the Fidelity 200 HeartLife Tempo Card, is a direct-to-consumer non-prescription flexible credit card- sized heart monitoring device which will be used as an early-detection device by patients who desire to independently monitor their condition. The HeartLife Tempo Card uses the award-winning amplification technology contained in Signalife's Fidelity 100 Heart Monitor. In operation, at the onset of an event that will be recorded, the patient will hold the event recorder to his/her chest, press the "record" button, and record up to a 45-second event. The event recorder will be capable of storing up to six, 45-second recordings. The patient will then either take the recorder to his or her physician for review, or transmit the data to a subscription-based 24-hour monitoring center where it can be immediately evaluated by a qualified ECG technician, cardiac nurse or cardiologist.


With the sensitivity of the amplification technology used in the Fidelity 200 HeartLife Tempo Card - developed by Signalife's Chief Technology Officer and renowned scientist Dr. Budimir Drakulic - the Company believes it will be able to allow patients to effectively monitor their hearts anytime, anyplace, without the necessity of a prescription or other physician intervention. This, in turn, will lead to additional care and may lead to earlier intervention and other preventative measures for cardiovascular disease - the most costly of all diseases nationwide with annual expenditures approaching $400,000,000 spent across the country.

Dr. Lowell Harmison - the Company's CEO and former official for the United States in various regulatory health care capacities, including Principal Deputy Assistant Secretary for Health of the U.S. Public Health Service, Department of Health and Human Services, commented: "I am gratified at the work of Dr. Drakulic and Signalife's Director of Regulatory Affairs, Bill Matthews, in bringing this dream to fruition. I have always talked about a 'level playing field,' which doesn't exist when patients have no ability to see the early warning signs and other signals of cardiovascular disease. It is one thing to be symptomatic. And it is quite another to learn about the warning signs when the symptoms are silent. The Fidelity 200 HeartLife Tempo Card is the beginning of that "sea change" in care that I have been referring to, when early detection can actually be realized. I believe the motto that Signalife has adopted for the HeartLife Tempo Card will be borne out by the use of this device - "it is better to have your HeartLife Card when you need it, than to need it and not have it'."

The FDA requires various fabrication and testing methodologies to be followed as the device moves into the marketplace. The Company is poised to quickly achieve these objectives, and anticipates that a final production model of the Fidelity 200 HeartLife Tempo Card will be introduced into the market in the first quarter of 2008.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.

[TechKim]

Heart disease killing more younger women
Obesity among factors blamed for rise in deaths from clogged arteries
http://www.msnbc.msn.com/id/21887502/


updated 5:04 p.m. ET, Mon., Nov. 19, 2007
ATLANTA - For decades, heart disease death rates have been falling. But a new study shows a troubling turn — more women under 45 are dying of heart disease due to clogged arteries, and the death rate for men that age has leveled off.

Heart experts aren’t sure what went wrong, but they think increasing rates of obesity and other risk factors are to blame.

The rates will have to be monitored to see if this is the beginning of a real trend. But if the data holds, the new study may be an early glimpse of the impact of escalating obesity and diabetes on U.S. deaths, said Wayne Rosamond, a University of North Carolina epidemiology professor and expert on heart disease statistics.

“This could be a harbinger of things to come,” Rosamond said.

To be sure, the overall trend is still positive: From 1980 through 2002, the death rate from blocked heart arteries was cut in half for men and women over 35. Improvements in treatment and preventive measures, including cholesterol-lowering medications, get the credit.

But what’s going on with younger adults is startling, said Dr. Anthony DeMaria, editor of the Journal of the American College of Cardiology, which is publishing the study and released it Monday.

“We have a pretty rosy view of how things are going in the war against cardiovascular disease,” DeMaria said. “I view this paper as a wake-up call that says there is a very important segment of our population that needs some attention.”

Heart disease is the leading cause of death in the United States, killing almost 700,000 Americans each year.

Nearly 500,000 of those deaths are attributed to coronary heart disease, in which fat and plaque clog the arteries feeding blood to the heart, sometimes called hardening of the arteries. Heart attacks are a common result.

It can take many years for arteries to get dangerously blocked. About 93 percent of deaths occur in people 55 and older.

But a combination of factors — including genetics, obesity and high cholesterol — are sometimes fatal for younger adults. In 2002, about 25,000 men and 8,000 women ages 35 to 54 died of coronary heart disease.

The study was done by researchers at the U.S. Centers for Disease Control and Control and Prevention and Britain’s University of Liverpool. They looked at U.S. vital statistics for artery-related deaths in adults ages 35 and older for the years 1980 through 2002, the most recent year for which data was available when the analysis was done.

When they compared age groups, they detected the worrisome difference. The study found the death rate for women ages 35 to 44 rose from 1997 to 2002, when the rate was 8.2 per 100,000 women, the highest it’s been since 1987.

In actual numbers, the increase amounts to roughly 100 added deaths a year of women in that age group. That’s a relatively small impact in the entire U.S. population.

Still, the results are statistically significant and a legitimate cause for concern, said Dr. Wayne Giles, director of the CDC’s division of adult and community health.

“That’s like an MD-88 crashing every year,” he said, referring to a medium-size commuter jet plane.

The rates for men age 35 to 44 were relatively stable in the last few years of the study period. The rate was 26 deaths per 100,000 men in that age group in 2002.

The fact the male rate didn’t worsen may indicate doctors are more likely to suspect heart disease in men that age than in women, said the CDC’s Dr. Earl Ford, a study co-author.

For all ages, the female death rate fell to 261 to 514 per 100,000; the male rate fell to 430 from 898 per 100,000.



© 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

[TechKim]

Giveline.com Purchases Benefit Scleroderma Foundation

The holiday season is upon us, and what better way to purchase gifts for your loved ones and friends while benefiting the Scleroderma Foundation at the same time. Through Giveline.com, online purchasers can order gifts from eight categories: books, movies, music, video games, electronics, home & kitchen, gifts & wine, and travel. The Web site will contribute between 7 and 33 percent of product sales to the Scleroderma Foundation, with a store-wide average of nearly 16 percent per transaction.

[TechKim]

No justified bottom! It swings!

[GONEOM]

anybody knows why the selloff...

[TechKim]

I do not know how many entraped investors there are. I previously posted I sold. My concern of falling back again was warranted on past history.

[benchman]

Thanks for the response. I wonder how many people could have a loss here. The stock was almost at it's highest level of the year only about 3 weeks ago.

[TechKim]

There is no bottom, as there is no operating revenue other than 3rd party financing. It could go either way depending on the type of seller that is in the mix of shares. We are going into tax selling season shortly.

[benchman]

Been buying this stock Friday and today. Anyone know of a fundamental reason why it has fallen so much lately?

TIA

Bench

[TechKim]

Did you buy more stock today?

[klonnie24]

What a nice hold on a garbage day......


although I sold most of my postition earlier in the month I still hold a few and with the down down 370 and SGN up .06....It was just kinda impressive, thats all.....Everyone good luck

[GONEOM]

nice.....eom

[TechKim]

Signalife Continues to Procure Purchase Orders, Revenues
Wednesday October 10, 9:15 am ET


LOS ANGELES, Oct. 10 /PRNewswire-FirstCall/ -- Signalife has received additional sales orders in excess of one half million dollars ($551,500 to be exact), during CEO Lowell Harmison's most recent cross-country sales initiative. These purchase orders are currently resulting in revenues to the company such that the company anticipates achieving break-even status by the end of January, 2008, or at the very latest the end of 2008 first quarter.